Press Releases

Pharmaceutical Packaging Market Size, Growth and Latest Insights 2025

The global pharmaceutical packaging market was valued at US$ 139.40 billion in 2023 and is projected to reach US$ 387.50 billion by 2034, expanding at a CAGR of 9.74% (2024–2034). North America held the dominant share of 36% in 2023, while Asia Pacific is expected to register the fastest growth. By material, plastics & polymers led the market in 2023, whereas paper & paperboard is set to expand significantly. By product, primary packaging (such as vials, syringes, bottles, blister packs) dominated and will remain the fastest-growing. Oral drugs led by drug delivery mode in 2023, while injectables are forecast to grow at the fastest CAGR (2024–2034). On the end-use side, pharma manufacturing dominated and will remain the leading contributor.

Download the free sample and get the complete insights and forecasts report on this market @ https://www.towardshealthcare.com/download-sample/5247

Table of Contents

Toggle

Market Size

◉2023 Market Value: US$ 139.40 billion

◉2034 Market Value: US$ 387.50 billion

◉CAGR (2024–2034): 9.74%

◉North America (2023 share): 36% of global revenue

◉Europe: Growing steadily, driven by biologics & eco-friendly innovations.

◉Asia Pacific: Fastest-growing region due to government investments, patient pool, and strong pharma base (China & India lead).

◉Latin America: Brazil & Mexico driving growth due to rising pharmaceutical exports.

◉Middle East & Africa (MEA): Emerging opportunities due to increased import dependency on pharma products.

Market Trends

Primary packaging supremacy + speed

◉Dominated 2023 and remains the fastest-growing product class: vials, ampoules, prefilled syringes, bottles, blisters.

◉Catalyst: surge in biologics/vaccines and sterile injectables.

Plastics & polymers = workhorse materials

◉2023 leader by material due to cost, weight, manufacturability; PVC, PET, PE, PP, PS central across bottles, blisters, closures, device housings.

Paper & paperboard acceleration

◉Significant growth outlook: sustainable secondary & tertiary packs, plus novel primary-adjacent concepts.

◉Example given: Push-Pak (Keystone, Jun 2024) → compact paperboard blister concept optimizes footprint.

Injectables outrun all drug-delivery modes

◉Fastest 2024–2034 CAGR due to biologics, GLP-1s, and complex therapies needing sterile, barrier-strong, device-integrated packs.

Smart/secure packaging mainstreaming

◉RFID/NFC/QR/holograms → anti-counterfeit, traceability, adherence.

◉IoT tie-ins for cold chain assurance and last-mile visibility.

Generics volume flywheel

◉Lower price points → higher SKU volumes → sustained demand for cost-optimized primary + secondary formats.

◉Your data point: Teva generic revenue US$ 8.734B (2023) and pipeline scale underline generic-led packaging volumes.

Circularity & recyclability inflection

◉CiPPPA (UK, Apr 2024) targets end-of-life recycling pathways.

◉Aluflexpack 4Form (Jul 2024) single-material lacquered aluminum blister.

◉SGD Pharma (Sep 2024) PCR glass campaign in China.

AI’s Impact

Quality & Compliance

◉Machine vision detects dents, cracks, misprints, fill-level anomalies; reduces escapes to near-zero at line speed.

◉Real-time SPC + AI drift detection flags subtle pattern shifts (seal integrity, torque variability), preventing batch rework/recall.

◉Example from your data: Sea Vision Group (Dec 2023) AI to elevate packaging quality/productivity.

Throughput & OEE

◉Predictive maintenance models for cartoners, blister thermoformers, vial washers/fillers → fewer unplanned stops; higher OEE.

◉Dynamic scheduling: AI re-sequences lots to minimize changeover, balancing sterilization windows & expiry constraints.

Material/Design Intelligence

◉AI-driven finite element & barrier simulations: optimize wall thickness, blister cavity geometry, headspace O₂ control → material savings without risking stability.

◉LCA optimizers: weigh CO₂e, recyclability, and cost under regulatory constraints (e.g., child-resistance, tamper-evidence).

Serialization & Anti-Counterfeit

◉AI cross-validates serials across line/cloud, detects copy/clone patterns, and triggers investigations.

◉Computer vision for microtext/hologram authenticity in QA sampling.

Cold Chain & Smart Packaging

◉Sensor data (temp/humidity/shock) + AI identifies route-risk corridors, anticipates excursions, and recommends packaging insulation upgrades or lane changes.

◉Adherence analytics (smart blisters) → insights for patient programs (pharma-sponsored), feeding demand planning.

Cost & Waste Reduction

◉Yield analytics pinpoint scrap sources (forming film wrinkles, label misfeeds).

◉Digital twins model new lines: avoid over/under-spec of capital.

Governance & GxP

◉AI audit trails & explainability layers structured for CSV (computer system validation) and data integrity expectations.

◉Bottom line: AI defends quality, cost, and speed simultaneously, and is decisive for injectables & smart pack success.

Regional Segments

North America (NA) — 36% share in 2023 (US$ 50.18B)

◉Demand engines: high prevalence of chronic disease; strong biologics & GLP-1 pipelines → vial/syringe/blister intensity.

◉Infrastructure: large base of CDER-recognized manufacturing sites; pharma maintains in-house primary packaging + validated suppliers.

◉What wins: compliant sterile containment (Type I glass, advanced elastomer closures), CR/SF (child-resistant/senior-friendly) Rx packs, robust serialization.

Asia Pacific (APAC) — Fastest growth

◉China: largest API producer; “Made in China 2025” → upstream self-reliance, downstream premiumization; PCR glass initiative (SGD) shows sustainability tilt.

◉India: 20% global generics share; ₹4,17,345 Cr (2023–24) pharma turnover → blister, bottle, strip packs at scale; value-engineering + compliance are key.

◉Japan/Korea: device-integrated injectables, high-precision prefilled syringes; demand for tight tolerances and cleanroom packaging.

Europe

◉Biologics/biosimilars drive temperature- & light-sensitive containment; thermo-protective primary packaging R&D (notably Germany).

◉Circularity: CiPPPA (UK) aligns value chain on end-of-life solutions; push for mono-material and recycled content (SGD PCR glass).

◉What wins: glass excellence, barrier films, re-processable formats, documented eco-footprint.

Latin America

◉Brazil/Mexico: rising pharma manufacturing and exports → formalization of GMP-compliant packaging supply, serialization adoption.

◉What wins: cost-efficient yet compliant secondary/tertiary packs, reliable cold-chain for biologics importation.

Middle East & Africa (MEA)

◉Import-led pharma consumption; expanding healthcare spend and specialty imports ⇒ demand for robust tertiary + insulated shippers.

◉What wins: validated cold-chain kits, counterfeit-resistant features, regional last-mile resilience.

Market Dynamics

Demand drivers

◉New medications (biologics, vaccines) → stringent primary containment.

◉Rising transportation volumes → reliable/sustainable packaging to defend against temperature, light, moisture, shock.

◉Biodegradable & eco-innovations → accelerate paper/paperboard & mono-material blisters.

Restraints

◉Strict regulation (patient safety, tamper-evidence, labeling, sterility).

◉Counterfeiting risks → added cost/complexity (serialization + smart features).

Opportunities

◉Smart packaging (hologram/NFC/RFID/QR) for track & trace and patient engagement.

◉Injectables outperformance (fastest-growing delivery mode 2024–2034).

◉Recycling initiatives (CiPPPA) and PCR materials (SGD) enable differentiated sustainability.

Risks & mitigations

◉Material volatility → dual-source critical films/resins; design for material substitution.

◉Regulatory change → proactive change control and modular packaging.

◉Counterfeit escalationtiered security (overt/covert/forensic) + analytics.

Leading Companies 2025

Amcor plcGlobal converter

◉Products: Flexible/rigid pharma formats (primary films, pouches, blisters; secondary cartons).

◉Strength: Scale + sustainability programs; broad GMP footprint.

WestRock CompanyFiber systems leader

◉Products: Paperboard cartons, CR/SF designs, inserts/leaflets.

◉Strength: Structural design, converting scale, sustainability credentials.

Berry Global, Inc.Plastic systems

◉Products: Bottles, closures, specialty components for pharma.

◉Strength: High-volume polymer conversion, closure systems.

Owens-Illinois (O-I)Glass containers

◉Products: Glass bottles/containers (pharma-use SKUs exist).

◉Strength: Glassmaking scale, barrier/inertness benefits.

Schott AGBorosilicate excellence

◉Products: Type I glass vials, syringes, ampoules.

◉Strength: High-purity glass for injectables.

SGD Pharma (your detailed data)Pharma glass specialist

◉Scale: 5 plants, 7 furnaces, 1 sorting, 1 decoration; 8M+ bottles/vials output; €441M turnover (2023).

◉Strength: Global production in EU & Asia; PCR glass campaign (2024) = sustainability leadership.

West Pharmaceutical Services, Inc.Injectable containment

◉Products: Stoppers, seals, device components; containment/closure systems.

◉Strength: Deep integration with biotech fill-finish.

Gerresheimer AGGlass & plastic pharma

◉Products: Vials, syringes, inhalation & device packaging.

◉Strength: Broad platform across primary + devices.

Vetter Pharma InternationalCDMO/packaging interface

◉Products: Fill-finish, combination product final assembly/packaging.

◉Strength: Sterile operations and device kitting.

CCL Industries, Inc.Labeling specialist

◉Products: Pharma labeling, security features.

◉Strength: Serialization-ready label systems.

Drug Plastics GroupRigid plastics

◉Products: Bottles, closures for Rx/OTC.

◉Strength: Regulatory-grade polymers, consistency.

Becton, Dickinson and Company (BD)Systems & devices

◉Products: Syringes, needles, systems integral to primary packaging.

◉Strength: Global standardization of syringe systems.

AptarGroup, Inc.Drug delivery pack

◉Products: Pumps, inhaler components, nasal/ophthalmic packaging.

◉Strength: Precision dosing, patient-centric usability.

International PaperFiber-based secondary/tertiary

◉Products: Cartons, shippers, inserts.

◉Strength: Large-scale paperboard supply.

Comar, LLCSpecialty plastics & devices

◉Products: Bottles, closures, precision components.

◉Strength: Custom molding for regulated markets.

PCI Pharma Services

◉2024: US$ 365M investment for injectables and combination products (clinical & commercial).

◉Strength: End-to-end assembly & packaging at scale; device-combo expertise.

Latest Announcements

PCI Pharma Services (Sep 2024)

◉US$ 365M infrastructure investment to support assembly & packaging for injectable drug-device combinations across clinical → commercial.

◉Implication: Capacity relief for pharma sponsors; faster tech-transfer; robust device kitting.

SGD Pharma (Sep 2024)

Completed first 20% PCR cullet glass campaign; introducing PCR glass bottles from Zhanjiang (China).

◉Implication: Measurable recycled content in primary glass, aligning with EU & global sustainability KPIs.

Recent Developments

◉Aluflexpack 4Form (Jul 2024): Single-material lacquered aluminum blister → improves recyclability vs multi-layer; keeps barrier performance high for oral solid doses.

◉CiPPPA (UK, Apr 2024): Industry coalition to solve end-of-life for primary pharma packs & medical devices; expects design-for-recycling migration and new takeback pathways.

◉Keystone Push-Pak (Jun 2024): Paperboard blister concept with compact cavity layout → cartonization efficiency, logistics density, and potential fiber-based primary-adjacent innovation.

◉Sea Vision AI (Dec 2023): AI-based inspection to raise quality & productivity; line-speed defect capture for cracks/dents.

◉Teva generics scale (2023): US$ 8.734B generics revenue; ~500 Rx items in market; 1,100 pipeline generics → sustained high-volume oral & secondary packaging demand.

Segments

A) By Material

1 Common forms 

◉PVC (thermoformed blisters): good formability; typically paired with foil lidding; can be coated or laminated for improved barrier.

◉PET (clarity/rigidity): bottles, thermoformed trays; good dimensional stability and transparency.

◉PE (HDPE/LDPE/LLDPE):

◉HDPE bottles for tablets/capsules; chemical resistance; good moisture barrier.

◉LDPE/LLDPE films, liners; flexibility for pouches/tubes.

◉PP (closures/containers): high heat resistance; autoclave-capable; low extractables profile when formulated correctly.

◉PS (rigid components): used where stiffness and shape retention matter.

Why they win (expanded):

◉Cost-to-performance: lowest $/unit at scale; high line speeds.

◉Processability: injection/blow molding, thermoforming, FFS compatible.

◉Weight: lowers shipping emissions/costs vs glass/metal.

◉Design freedom: living hinges, child-resistant closures, tamper evidence built in.

Engineering & compliance considerations:

Barrier: native O₂/H₂O barrier varies; often boosted with films, coatings, or foil lidding.

Sterilization compatibility (select by resin/grade): steam, EtO, radiation—assess property shifts (e.g., brittleness, discoloration).

E&L (extractables/leachables): resin, colorants, and additives must meet toxicological thresholds; run risk-based E&L studies aligned to drug profile.

Aging & creep: ensure torque retention for caps; validate seal integrity over shelf life.

Recyclability: mono-material designs simplify end-of-life; avoid mixed laminates where possible.

2 Paper & Paperboard (fast growth)

Uses: secondary cartons, leaflets, shipper cases; rising paperboard blister concepts (as in your Push-Pak example).

Drivers: sustainability targets, recyclability, lower packaging weight, regulatory encouragement for fiber-based secondaries.

Engineering notes:

◉Strength & humidity: specify caliper/BF/ECT for supply chain stress; add moisture resistance coatings where needed.

◉Print & legibility: serialization/2D codes must remain scannable post-distribution; manage ink rub/abrasion.

◉Child-resistant (CR)/senior-friendly (SF): fiber-based mechanisms (push-through resistance, tear paths) require usability testing.

3 Glass

◉Type I borosilicate for injectables (vials/ampoules/prefilled syringes).

◉Why critical: chemical inertness, thermal resistance, proven sterility pathway and container–closure integrity (CCI).

Engineering notes:

◉Delamination control: specify composition/processing to reduce lamellae risk with certain formulations (low pH, chelators).

◉Dimensional tolerances: crucial for stopper fit and device assembly (autoinjectors).

◉Surface treatment & siliconization: manage protein adsorption vs particle risk; validate silicone levels.

◉PCR glass (your data): 20% cullet campaigns improve circularity with controlled quality.

4 Aluminum Foil

◉Use: blister lidding, barrier wraps, cold-form blisters (with laminates).

◉Why: excellent moisture/oxygen/light barrier for OSD (oral solid dose).

Design notes:

◉Lidding sealability: heat-sealable lacquer tuned to PVC/PVDC/PET films.

◉Single-material innovations: your 4Form example (lacquered aluminum) targets recyclability and barrier maintenance.

B) By Product

1) Primary (dominant & fastest-growing)

◉Forms: plastic bottles, vials/ampoules, prefilled syringes, blister packs, inhalers, pouches, tubes.

◉Role: direct contact with drug; ensure stability, sterility (where applicable), CCI, and low E&L.

◉Development checkpoints:

◉Compatibility/stability: sorption, permeation, pH shift, light sensitivity.

◉CCI methods: probabilistic (dye ingress) vs deterministic (vacuum/pressure decay, tracer gas—a helium approach—, laser headspace).

◉Particulates: control visible/subvisible for parenterals.

◉Device interfaces: stoppers/plungers, needles, cannulas; break-loose/glide forces for PFS.

◉Sterilization validation: SAL targets; impact on polymer or elastomer properties.

2) Secondary

◉Forms: cartons, leaflets, prescription containers, accessories (spoons, adapters).

◉Role: branding/ID, information, tamper evidence, CR/SF features; carrier for serialization (GTIN/2D code).

◉Key controls: barcode print quality, leaflet fold integrity, carton compression strength, glue seam robustness.

3) Tertiary

◉Forms: cases, pallets, insulated shippers (for cold chain).

◉Role: distribution protection; thermal control for 2–8 °C or frozen lanes (specify phase-change materials, insulation R-value).

◉Qualification: lane-based thermal profiles; drop/stack testing; route risk mapping.

C) By Drug Delivery Mode

1 Oral Drugs (2023 leader)

◉Package focus: moisture/light protection for OSD; desiccants for hygroscopic APIs; child-resistance for Rx.

◉Operations: high-speed blister lines (forming → feeding → sealing → punch); bottle lines (filling → cotton/desiccant → capping → induction seal → label → case).

2 Injectables (fastest growth 2024–2034)

◉Package focus: sterile glass vials/PFS/ampoules; elastomer selection (extractables, resealability), CCI assurance, low tungsten risk for some staked needles.

◉Device combos: autoinjectors, safety needles—tight tolerance stack-ups and assembly validation.

◉Others (topical/ophthalmic/nasal/pulmonary/transdermal/IV)

◉Specialized components: pumps (dose uniformity, priming), droppers (drop size), inhalers (aerosol performance), IV bags (compatibility/plasticizer control), patches (adhesive performance).

D) By End-Use

1 Pharma Manufacturing (largest & fastest)

In-house primary packaging rooms (cleanroom classifications), bespoke designs (anti-counterfeit features), validated warehouses (FEFO, temp mapping).

◉Change control discipline: any component tweak triggers comparability impact assessment.

2 Contract Packaging (CP/CMO/CDMO)

◉Scale-up flexibility, surge capacity, late-stage customization (LSC), multi-format line flexibility; formal quality agreements and tech transfer playbooks.

3 Retail & Institutional Pharmacy

◉Unit-dose prep, blistering for adherence, hospital ready-to-administer kits; labeling controls aligned to hospital systems.

E) By Region — Orientation

◉NA/Europe/APAC/LATAM/MEA per your deep-dive: NA currently largest (36%), APAC fastest growth, Europe sustainability/biologics push, LATAM formalizing GMP/serialization, MEA import-led with cold-chain emphasis.

Product Safety & Regulatory Posture — What Matters

1 Identity & integrity

◉Tamper-evident bands/labels; serialization + aggregation (unit→bundle→case→pallet).

◉Human factors: readability, error-proofing (look-alike/sound-alike mitigation).

2 Stability/Protection

◉Barrier to O₂/H₂O/light; foil lidding for OSD; amber glass/UV coatings for photosensitive drugs.

◉CCI strategy across shelf life and distribution stress (vibration, pressure, temperature excursions).

3 Sterility

Depyrogenation (glass), sterilization cycle validation (PFS/vials); audit trail for aseptic processing.

4 Compliance System

◉Documentation: component specs/CoAs, master batch records, validated inspection methods.

◉Traceability: lot genealogy from raw to released pack.

◉Change control: risk-based, with stability/CCI re-verification rules.

◉CR/SF where mandated: validated with user panels.

Value Chain & KPIs — How Leaders Execute

Upstream

◉Materials → intermediates → components

Control grade, additives, and COA acceptance criteria.

◉Incoming QA: ID/FTIR where appropriate; dimensional checks; print/ink adhesion for fiber parts.

Midstream (Fill-Finish & Pack)

◉Core KPIs & how to use them:

◉Line speed (units/hr) & OEE = Availability × Performance × Quality; trend by SKU to spot format drag.

◉Defect ppm (per failure mode: misprint, underfill, seal defect).

◉CCI pass-rate (% lots meeting deterministic thresholds).

◉Serialization conformance: scan/read rates, rework %, aggregation accuracy.

◉Yield (FPY): first-pass-yield across forming/filling/sealing without rework.

Downstream (Logistics)

◉Lane risk scoring (ambient vs 2–8 °C vs frozen); excursion rate (% shipments breaching temp windows).

◉Returns/complaints ppm: monitor complaint categories (leaker, label, carton damage).

Sustainability KPIs

◉Recycled content % (e.g., PCR glass share).

◉Mono-material adoption (% SKUs with recyclable single-material designs).

◉CO₂e/pack (use LCA baselines); recyclability score by market.

Quality KPIs

◉FPY, CAPA closure time, inspection sensitivity/specificity (avoid false passes; tune vision AI thresholds).

Cost KPIs

◉Material utilization (% waste on web/sheet), scrap % by station, changeover time, labor/energy per 1,000 units.

Top 5 FAQs

Q1. What is the global market size of pharmaceutical packaging?
A1. Valued at US$ 139.40B (2023), expected to reach US$ 387.50B (2034) at a 9.74% CAGR.

Q2. Which region dominates the pharmaceutical packaging market?
A2. North America (36% share in 2023).

Q3. Which is the fastest-growing region?
A3. Asia Pacific, driven by China’s API dominance and India’s generic exports.

Q4. Which segment dominates by product type?
A4. Primary packaging (vials, bottles, blister packs).

Q5. What are the latest innovations in pharma packaging?
A5. Smart packaging (RFID, QR, IoT), recyclable 4Form aluminum blisters, Push-Pak paperboard packs, and PCR glass bottles.

Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5247

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Powering Healthcare Leaders with Real-Time Insights: https://www.towardshealthcare.com/healthcare-intelligence-platform

Europe Region – +44 778 256 0738

North America Region – +1 8044 4193 44

Web: https://www.towardshealthcare.com

Find us on social platforms: LinkedInTwitterInstagram | Medium | Pinterest

sanskruti sathe

Recent Posts

Nebulizer Devices Market Size, Growth, Trends, Forecast and Insights 2025

The global nebulizer devices market was valued at US$ 1.17 billion in 2023 and is projected to reach US$ 2.2… Read More

9 hours ago

Child Care Market Overview, Trends, Growth and In Dept Insights 2025

The global child care market was valued at US$ 231.90 billion in 2024 and is projected to reach US$ 245.10… Read More

10 hours ago

Plasmid DNA Manufacturing Market Growth, Size and Forecast 2025

The global plasmid DNA manufacturing market was valued at US$ 1.85 billion in 2023 and is projected to grow to… Read More

11 hours ago

Perfusion Systems Market Insights, Forecast and Overview 2025

The global perfusion systems market was valued at US$ 1.15 billion in 2023 and is projected to grow to US$… Read More

11 hours ago

Nootropics Market Overview, Trends, Growth and Forecast 2025

The global nootropics market size reached USD 5.71 billion in 2025 and is projected to grow to USD 19.53 billion… Read More

3 days ago

U.S. Concierge Medicine Market Forecast, Growth and Trends 2025

The U.S. concierge medicine market was valued at USD 7.25 billion in 2024, grew to USD 8 billion in 2025,… Read More

3 days ago